Sandhoff Disease

Overview

Sandhoff disease is a rare inherited lysosomal storage disorder caused by disease-causing changes in both copies of the HEXB gene. The missing or severely reduced beta-hexosaminidase activity prevents cells from breaking down GM2 ganglioside, a fatty substance that then accumulates—especially in the brain and nervous system—causing progressive nerve-cell damage. The disease spans infantile, juvenile, and late-onset forms; the infantile form usually begins before 6 months of age with loss of developmental skills, low muscle tone, an exaggerated startle response, seizures, feeding difficulties, and progressive neurologic decline. GeneReviews: Sandhoff Disease

Prognosis depends strongly on residual enzyme activity. Infantile disease is usually fatal in early childhood, juvenile disease commonly progresses through childhood and adolescence, while some late-onset forms progress slowly over decades. There is still no approved therapy that corrects the underlying enzyme deficiency; current care is multidisciplinary and supportive, including seizure treatment, nutrition and hydration support, aspiration prevention, respiratory care, physical and occupational therapy, communication support, and palliative care when appropriate. GeneReviews: Sandhoff Disease

Scope of Recent Research (2020–present)

Research since 2020 has become substantially more translational: investigators are testing whether restoring hexosaminidase activity through gene transfer can slow disease in children, while also developing simpler single-vector gene therapies, genome-editing strategies, enzyme-delivery technologies, and cell-based approaches. The field is not yet at a proven cure, but the 2025 first-in-human Phase I/II results for dual-vector gene therapy and FDA authorization in July 2026 for a second-generation trial mark a meaningful transition from animal proof-of-concept studies to iterative clinical development. Dual-vector rAAVrh8 gene therapy trial UMass Chan Phase I/II authorization

Major Breakthroughs and Emerging Therapies

The leading curative strategy is adeno-associated virus (AAV) gene therapy. AAV is a modified, non-replicating virus used to deliver working gene copies to cells. In the first published Phase I/II GM2-gangliosidosis study, investigators delivered separate AAVrh8 vectors carrying HEXA and HEXB through bilateral thalamic brain infusion plus cerebrospinal-fluid routes. The nine participants included two children with Sandhoff disease and seven with Tay-Sachs disease. Across the combined cohort, enzyme activity and disease-related biochemical measures improved in a dose-related manner; the highest-dose group showed measurable central nervous system enzyme activity, increased serum total hexosaminidase activity, and imaging evidence consistent with improved white-matter tracts. Dual-vector rAAVrh8 gene therapy trial

Large-animal work has helped define both the potential and the limits of this approach. In symptomatic Sandhoff cats, direct brain administration of AAVrh8 vectors carrying feline HEXA and HEXB distributed enzyme broadly in the central nervous system and delayed progression, with greater benefit when treatment began earlier in the symptomatic period. Symptomatic feline AAV gene therapy A longer-term feline study found that effective brain correction substantially extended survival—treated cats lived an average of 19.1 months versus 4.4 months for untreated cats—but unmasked serious disease outside the brain, including gastrointestinal, urinary, and orthopedic complications. Peripheral disease after CNS gene therapy

A major engineering goal is to avoid needing two separate vectors, which complicates manufacturing and requires both vectors to reach the same cells. A 2026 preclinical study tested an AAV9-derived vector carrying a modified HEXB gene designed to produce an enzyme capable of performing the GM2-clearing role normally requiring the alpha and beta subunits together. In Sandhoff mice, the therapy reduced GM2 storage and neuroinflammation while improving motor function and survival; intrathecal dosing in rats and nonhuman primates showed broad distribution in preclinical safety studies. Modified HEXB AAV therapy

Genome editing remains earlier-stage but conceptually attractive. In a 2020 Sandhoff mouse study, AAV-delivered CRISPR editing inserted an engineered, GM2-clearing HEXM sequence into the liver albumin locus, turning liver cells into a long-term source of secreted corrective enzyme. The intervention increased enzyme activity, reduced storage in several tissues, and improved motor performance, although brain correction was incomplete. CRISPR-HEXM editing in Sandhoff mice Cell-based research has also expanded: a 2025 mouse study showed that replacing diseased brain microglia—immune cells that normally supply beta-hexosaminidase—with enzyme-competent cells restored enzyme activity, reduced substrate accumulation, and improved behavior. Microglial replacement in Sandhoff mice

Clinical Trials and Experimental Approaches

The most important completed early clinical program is AXO-AAV-GM2, initially sponsored by Axovant/Sio Gene Therapies and subsequently completed under an investigator-sponsored IND after the corporate sponsor withdrew. The Phase I/II program, registered as NCT04669535, used dual AAVrh8-HEXA and AAVrh8-HEXB vectors. Its published report found dose-related biochemical activity and suggested clinical stabilization or slower-than-expected regression in infantile participants, but outcomes were based on a very small, mixed Tay-Sachs/Sandhoff cohort with limited follow-up. Immune-related liver-enzyme elevations occurred and were managed with corticosteroids; juvenile participants experienced worsening dystonia and were excluded from further enrollment. Dual-vector rAAVrh8 gene therapy trial

N-acetyl-L-leucine (levacetylleucine) is not a cure because it does not restore HEXB function, but it is a notable disease-modifying symptomatic approach. In a multinational, open-label, rater-blinded Phase IIb study involving children and adults with GM2 gangliosidoses, participants improved on the primary blinded video-based endpoint during treatment and worsened during washout; the study reported no treatment-related serious adverse events. N-acetyl-L-leucine Phase IIb study On July 21, 2026, UMass Chan announced FDA authorization to proceed with a new Phase I/II study of a second-generation AAV gene therapy designed to improve delivery at lower doses; as of August 8, 2026, this is an authorized investigational program rather than an established treatment. UMass Chan Phase I/II authorization

Methodologies and Scientific Approaches

Researchers use complementary disease models because no single model captures every feature of human Sandhoff disease. Hexb-deficient mice enable relatively rapid testing of enzyme activity, GM2 storage, inflammation, movement, survival, and new approaches such as CRISPR editing or microglial replacement. Sandhoff cats provide a much larger brain and a disease course useful for evaluating surgical delivery, vector distribution, magnetic resonance imaging, long-term survival, and complications outside the central nervous system. Symptomatic feline AAV gene therapy Peripheral disease after CNS gene therapy

Clinical and preclinical studies increasingly combine biochemical, imaging, and functional measures. These include hexosaminidase activity in blood and cerebrospinal fluid, GM2 species measured by liquid chromatography–tandem mass spectrometry, magnetic resonance imaging, diffusion tensor imaging of white-matter tracts, developmental testing, seizure assessments, swallowing and oral-feeding status, and immune monitoring for AAV capsid responses. Dual-vector rAAVrh8 gene therapy trial

Leading Institutions and Funding

UMass Chan Medical School, Massachusetts General Hospital, Auburn University, and collaborating centers including the NIH have driven much of the recent gene-therapy pipeline, spanning feline studies, neurosurgical delivery, biomarker development, and the initial clinical trial. The current second-generation effort is led at UMass Chan by Heather Gray-Edwards and Miguel Sena-Esteves. UMass Chan Phase I/II authorization The first Phase I/II study was supported by the National Tay-Sachs & Allied Diseases Association (NTSAD), Cure Tay-Sachs Foundation, Blu Genes Foundation, Mathew Forbes Romer Foundation, and the UMass Chan Horae Gene Therapy Center. Dual-vector rAAVrh8 gene therapy trial

Patient-led funding is especially consequential in this ultra-rare field. In 2025, NTSAD awarded $365,000 to UMass Chan for second-generation GM2 gene-therapy work, within a collaborative $870,000 award involving NTSAD, Blu Genes Foundation, Cure Tay-Sachs Foundation, and Mathew Forbes Romer Foundation. NTSAD has also funded early work on nanoparticle-distributed intravenous enzyme replacement and hematopoietic stem-cell gene therapy concepts for GM2 disorders. NTSAD research grants

Strengths, Limitations, and Challenges

The central strength of gene therapy is that even partial, durable restoration of lysosomal enzyme activity could address the root cause rather than only relieving symptoms. The first human study demonstrated that the vectors reached biologically relevant targets and produced dose-related biochemical effects, while the animal literature shows that enzyme secreted from corrected cells can help nearby uncorrected cells—a phenomenon called cross-correction. Dual-vector rAAVrh8 gene therapy trial Modified HEXB AAV therapy

However, no current approach has shown that it can permanently halt or reverse Sandhoff disease in a sufficiently large human cohort. Key barriers include treating children after irreversible neuron loss has begun, reaching the full brain and spinal cord safely, sustaining enzyme expression, managing pre-existing or treatment-induced anti-AAV immunity, and treating peripheral organs as well as the central nervous system. The first trial showed declining enzyme activity after its 12-week peak and clinically important safety signals in juvenile participants, while feline work demonstrated that a brain-focused therapy can leave life-limiting disease elsewhere in the body. Dual-vector rAAVrh8 gene therapy trial Peripheral disease after CNS gene therapy

Outlook and Future Directions

Sandhoff disease research is closer to a root-cause treatment than it was in 2020, but it is not yet close to a confirmed cure. The milestones to watch are enrollment and early safety data from UMass Chan’s second-generation Phase I/II program, evidence that a single-vector or engineered-enzyme platform can produce broader and more durable correction, and proof that treatment improves meaningful outcomes such as developmental stability, seizure burden, swallowing, mobility, and survival without creating unacceptable immune or peripheral-organ risks. The most plausible future regimen may combine early gene therapy with improved CNS and systemic delivery, objective biomarkers, and adjunct treatments that reduce inflammation or residual substrate burden. UMass Chan Phase I/II authorization Microglial replacement in Sandhoff mice

References

• Sandhoff Disease — GeneReviews®, 2025.
• Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial — Eichler et al., Nature Medicine, 2025.
• UMass Chan researchers receive FDA authorization to advance gene therapy clinical trial for Tay-Sachs and Sandhoff diseases — UMass Chan Medical School, 2026.
• Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease — McCurdy et al., Gene Therapy, 2021.
• Life-Limiting Peripheral Organ Dysfunction in Feline Sandhoff Disease Emerges after Effective CNS Gene Therapy — Johnson et al., Annals of Neurology, 2023.
• AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models — Kitakaze et al., Cell Reports Medicine, 2026.
• A novel gene editing system to treat both Tay–Sachs and Sandhoff diseases — Ou et al., Gene Therapy, 2020.
• Microglial replacement in a Sandhoff disease mouse model reveals myeloid-derived β-hexosaminidase is necessary for neuronal health — Tsourmas et al., Nature Communications, 2025.
• A Dose-escalation and Safety & Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease — ClinicalTrials.gov, 2026.
• Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses — Kaya et al., Neurology: Clinical Practice, 2023.
• NTSAD Grant Opportunities — National Tay-Sachs & Allied Diseases Association, 2026.